CAS 1620574-24-4

DLK-IN-1

CAS: 1620574-24-4

DLK-IN-1 is a synthetic small-molecule inhibitor, which is a product derived from targeted chemical synthesis with the specific aim of modulating the function of certain kinases. This inhibitor is sourced through advanced laboratory techniques that allow for precision-targeting of proteins involved in cellular signaling pathways. DLK-IN-1 specifically inhibits the dual leucine zipper kinase (DLK), a protein kinase involved in neuronal regeneration and degeneration pathways. By binding to the ATP-binding site of DLK, it prevents the phosphorylation of downstream substrates, thus modulating the DLK-mediated signaling cascade.

The utilization of DLK-IN-1 primarily lies in neurological research, particularly in understanding and potentially mitigating neurodegenerative diseases and nerve injury responses. It is instrumental in studying the roles of DLK in axonal degeneration and regeneration, providing insights into therapeutic approaches for conditions like Alzheimer's, Parkinson's, and other neurodegenerative disorders. Researchers employ DLK-IN-1 to dissect the DLK signaling mechanism, aiming to discover novel intervention points within neuronal repair and deterioration processes. The specificity and action of DLK-IN-1 make it a crucial tool for probing deeper into the molecular underpinnings of nerve health and disease.

Formula: C₂₀H₂₄F₃N₅O₂

Purity: Min. 95%

Molecular weight: 423.4 g/mol

Ref: 3D-VPC57424

DLK-IN-1

CAS: 1620574-24-4

DLK-IN-1: Oral DLK (MAP3K12) inhibitor, Ki=3nM, effective in Alzheimer's model, CNS permeable, well-tolerated with sustained brain levels.

Formula: C₂₀H₂₄F₃N₅O₂

Color and Shape: Solid

Molecular weight: 423.43

Ref: TM-T11056